drugset / Trial / NCT04579757
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
Timeline
- Start
- 2021-03-05
- Primary completion
- 2024-04-30
- Completion
- 2024-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | — | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |